TORONTO, April 12, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that PharmaTher has entered into an exclusive worldwide license agreement with Gesval S.A., a public limited company incorporated by the University of Liège, Belgium, for the development and…


Previous articleNuminus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
Next articleMindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium